Ustekinumab biosimilar (Amgen)

乌司奴单抗生物类似药 (安进)

Report date: 2026/05/26 20:00:28

Base Information

Drug NameUstekinumab biosimilar (Amgen)
Drug Alias NameUstekinumab-AUUBustekinumab-auubWezlanaWEZLANAwezenla +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 subunit beta inhibitorsInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12 subunit betaInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/10/31
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Technology (Ireland) Unlimited CompanyAmgen Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A